MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. CYH
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Community Health Systems (CYH) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Community Health Systems
NYSE•Healthcare•Medical Care Facilities
$2.41-0.25(-0.09%)Pre-market
Market Cap
$284.64M
P/E
7.9x
P/S
0.0x

Community Health Systems, Inc. owns, leases, and operates general acute care hospitals in the United States. The company offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services. It also provides outpatient services at primary care practices, urgent care centers, free-standing emergency departments, ambulatory surgery centers, imaging and diagnostic centers, and direct-to-consumer virtual health visits. Community Health Systems, Inc. was founded in 1985 and is headquartered in Franklin, Tennessee.

D

How this company scores

WeakMetricSide Score: 25/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Balance Sheet & Red Flags (8/25); weakest: Growth (3/25).

Profitability6/25
Growth3/25
Balance Sheet & Red Flags8/25
Cash & Earnings Quality8/25
Grade capped at D
  • Negative equity — the balance sheet is insolvent.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 7.9x5y range 0.8x – 12.1x
P/E 7.9x · above its 10-quarter median

Currently above its 10-quarter median.

P/S · 0.0x5y range 0.0x – 0.1x
P/S 0.0x · below its 20-quarter median

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Earnings Quality

Red Flag

FCF consistently trails net income (avg 0.4x) — earnings may be inflated by non-cash items or aggressive accounting.

Revenue Decline

Red Flag

Revenue declined in 6 of the last 7 quarters — persistent contraction signals a fundamental problem.

Price & Volume
Market Cap $284.64M

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$11.65B
6Q
Q. Revenue
$2.76B
3Q
TTM EBITDA
$1.70B
2Q
TTM Op. Income
$1.26B
3Q
Q. Op. Income
$146.00M
40%
TTM Net Income
$36.00M
3Q
Q. Net Income
$-86.00M
166%
EPS
$-0.63
165%
Shares Out.
$135.54M
7Q
$11.65B in TTM revenue declined 7.8% YoY, reaching $2.76B last quarter. TTM EBITDA of $1.70B and TTM operating income of $1.26B show growth is flowing through to the bottom line. TTM net income of $36.00M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has fallen for 6 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
85.2%
0%
EBITDA Margin
9.1%
20%
Op. Margin
5.3%
33%
Net Margin
-3.1%
174%
Op. margin of 5.3% is down 2.6% YoY — costs are rising relative to revenue. Net margin at -3.1% and gross margin of 85.2% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 33% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
7.9x
2Q
P/S Ratio
0.0x
26%
P/B Ratio
N/A
At 7.9x P/E, the stock trades below typical market levels. P/S of 0.0x and P/B of 0.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 5 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$12.11B
7Q
Cash
$155.00M
26%
Long-Term Debt
$9.57B
10%
Book Value
$-1.49B
1%
D/E Ratio
N/A
Debt/EBITDA
38.0
26%

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$154.00M
2Q
TTM Free Cash Flow
$-122.00M
2Q
FCF Margin
-1.0%
2Q
FCF / Net Income
-3.4
4Q
TTM FCF of $-122.00M on $154.00M in operating cash flow. The FCF / Net Income ratio of -3.4x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General

Cash Burn

Watch

FCF turned negative in 2 of the last 8 quarters — occasional cash consumption.

Share Dilution

Watch

Shares outstanding rose 2.4% — mild dilution. Compare to earnings growth to assess the net per-share impact.